Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules

Trial Profile

Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 16 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Oct 2008, as reported by ClinicalTrials.gov.
    • 16 Sep 2008 New data presented at Third European Influenza Conference (ESWI) according to GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top